Emergent BioSolutions Inc. (EBS)
USD 8.16
(-7.17%)
USD 8.16
(-7.17%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.83 Billion USD | -42.05% |
| 2022 | 3.16 Billion USD | 7.02% |
| 2021 | 2.95 Billion USD | 2.63% |
| 2020 | 2.88 Billion USD | 23.78% |
| 2019 | 2.32 Billion USD | 4.48% |
| 2018 | 2.22 Billion USD | 108.32% |
| 2017 | 1.07 Billion USD | 10.32% |
| 2016 | 970.11 Million USD | -7.04% |
| 2015 | 1.04 Billion USD | 10.4% |
| 2014 | 945.26 Million USD | 50.85% |
| 2013 | 626.63 Million USD | 11.06% |
| 2012 | 564.23 Million USD | 3.18% |
| 2011 | 546.86 Million USD | 9.3% |
| 2010 | 500.31 Million USD | 45.15% |
| 2009 | 344.68 Million USD | 18.54% |
| 2008 | 290.78 Million USD | 6.32% |
| 2007 | 273.5 Million USD | 14.8% |
| 2006 | 238.25 Million USD | 137.47% |
| 2005 | 100.33 Million USD | 45.29% |
| 2004 | 69.05 Million USD | 0.0% |
| 2002 | 22.79 Million USD | -10.36% |
| 2001 | 25.42 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.51 Billion USD | -16.08% |
| 2024 Q1 | 1.8 Billion USD | -1.71% |
| 2023 Q1 | 2.94 Billion USD | -6.85% |
| 2023 Q3 | 1.89 Billion USD | -13.11% |
| 2023 Q2 | 2.17 Billion USD | -26.14% |
| 2023 FY | 1.83 Billion USD | -42.05% |
| 2023 Q4 | 1.83 Billion USD | -3.07% |
| 2022 FY | 3.16 Billion USD | 7.02% |
| 2022 Q2 | 2.73 Billion USD | -1.62% |
| 2022 Q1 | 2.78 Billion USD | -6.04% |
| 2022 Q3 | 2.9 Billion USD | 6.33% |
| 2022 Q4 | 3.16 Billion USD | 8.87% |
| 2021 Q2 | 2.91 Billion USD | 0.52% |
| 2021 Q1 | 2.9 Billion USD | 0.59% |
| 2021 Q4 | 2.95 Billion USD | 3.19% |
| 2021 Q3 | 2.86 Billion USD | -1.64% |
| 2021 FY | 2.95 Billion USD | 2.63% |
| 2020 Q4 | 2.88 Billion USD | 10.2% |
| 2020 FY | 2.88 Billion USD | 23.78% |
| 2020 Q1 | 2.27 Billion USD | -2.17% |
| 2020 Q2 | 2.46 Billion USD | 8.22% |
| 2020 Q3 | 2.61 Billion USD | 6.09% |
| 2019 Q2 | 2.32 Billion USD | 7.78% |
| 2019 Q1 | 2.15 Billion USD | -3.4% |
| 2019 FY | 2.32 Billion USD | 4.48% |
| 2019 Q3 | 2.33 Billion USD | 0.54% |
| 2019 Q4 | 2.32 Billion USD | -0.19% |
| 2018 FY | 2.22 Billion USD | 108.32% |
| 2018 Q1 | 1.06 Billion USD | -0.16% |
| 2018 Q2 | 1.13 Billion USD | 6.59% |
| 2018 Q4 | 2.22 Billion USD | 89.96% |
| 2018 Q3 | 1.17 Billion USD | 3.05% |
| 2017 Q4 | 1.07 Billion USD | 4.49% |
| 2017 Q2 | 970.48 Million USD | 1.98% |
| 2017 FY | 1.07 Billion USD | 10.32% |
| 2017 Q1 | 951.63 Million USD | -1.9% |
| 2017 Q3 | 1.02 Billion USD | 5.54% |
| 2016 Q3 | 932.02 Million USD | -11.78% |
| 2016 FY | 970.11 Million USD | -7.04% |
| 2016 Q4 | 970.11 Million USD | 4.09% |
| 2016 Q2 | 1.05 Billion USD | 1.99% |
| 2016 Q1 | 1.03 Billion USD | -0.74% |
| 2015 Q4 | 1.04 Billion USD | 6.87% |
| 2015 Q2 | 943.32 Million USD | 2.78% |
| 2015 Q1 | 917.84 Million USD | -2.9% |
| 2015 FY | 1.04 Billion USD | 10.4% |
| 2015 Q3 | 976.54 Million USD | 3.52% |
| 2014 Q2 | 837.24 Million USD | 1.7% |
| 2014 FY | 945.26 Million USD | 50.85% |
| 2014 Q3 | 869.29 Million USD | 3.83% |
| 2014 Q1 | 823.25 Million USD | 31.38% |
| 2014 Q4 | 945.26 Million USD | 8.74% |
| 2013 Q1 | 538.38 Million USD | -4.58% |
| 2013 Q3 | 595.46 Million USD | 7.17% |
| 2013 Q2 | 555.61 Million USD | 3.2% |
| 2013 Q4 | 626.63 Million USD | 5.23% |
| 2013 FY | 626.63 Million USD | 11.06% |
| 2012 FY | 564.23 Million USD | 3.18% |
| 2012 Q2 | 527.14 Million USD | 2.42% |
| 2012 Q3 | 540.02 Million USD | 2.44% |
| 2012 Q4 | 564.23 Million USD | 4.48% |
| 2012 Q1 | 514.68 Million USD | -5.88% |
| 2011 Q2 | 493.98 Million USD | 4.82% |
| 2011 FY | 546.86 Million USD | 9.3% |
| 2011 Q1 | 471.27 Million USD | -5.8% |
| 2011 Q3 | 512.96 Million USD | 3.84% |
| 2011 Q4 | 546.86 Million USD | 6.61% |
| 2010 FY | 500.31 Million USD | 45.15% |
| 2010 Q2 | 345.74 Million USD | 0.86% |
| 2010 Q1 | 342.79 Million USD | -0.55% |
| 2010 Q4 | 500.31 Million USD | 36.61% |
| 2010 Q3 | 366.23 Million USD | 5.93% |
| 2009 Q1 | 303.78 Million USD | 4.47% |
| 2009 Q4 | 344.68 Million USD | 8.8% |
| 2009 FY | 344.68 Million USD | 18.54% |
| 2009 Q3 | 316.8 Million USD | -2.94% |
| 2009 Q2 | 326.38 Million USD | 7.44% |
| 2008 Q3 | 287.39 Million USD | 3.41% |
| 2008 Q2 | 277.91 Million USD | 1.56% |
| 2008 Q1 | 273.64 Million USD | 0.05% |
| 2008 FY | 290.78 Million USD | 6.32% |
| 2008 Q4 | 290.78 Million USD | 1.18% |
| 2007 Q4 | 273.5 Million USD | 20.62% |
| 2007 FY | 273.5 Million USD | 14.8% |
| 2007 Q2 | 206.99 Million USD | 1.52% |
| 2007 Q1 | 203.89 Million USD | -14.42% |
| 2007 Q3 | 226.75 Million USD | 9.54% |
| 2006 FY | 238.25 Million USD | 137.47% |
| 2006 Q4 | 238.25 Million USD | 82.11% |
| 2006 Q3 | 130.83 Million USD | 0.0% |
| 2005 Q4 | 100.33 Million USD | 0.0% |
| 2005 FY | 100.33 Million USD | 45.29% |
| 2004 FY | 69.05 Million USD | 0.0% |
| 2004 Q4 | 69.05 Million USD | 0.0% |
| 2002 FY | 22.79 Million USD | -10.36% |
| 2001 Q4 | 2.95 Billion USD | 0.0% |
| 2001 FY | 25.42 Million USD | 0.0% |
| 2000 Q4 | 3.16 Billion USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 3.47 Billion USD | 47.16% |
| Bausch Health Companies Inc. | 27.35 Billion USD | 93.291% |
| Catalent, Inc. | 9.75 Billion USD | 81.186% |
| Elanco Animal Health Incorporated | 14.36 Billion USD | 87.224% |
| Perrigo Company plc | 10.8 Billion USD | 83.024% |
| Teva Pharmaceutical Industries Limited | 43.47 Billion USD | 95.78% |
| Zoetis Inc. | 14.28 Billion USD | 87.156% |